The European Leadership Summit on Chronic Care

3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the event will convene senior executives from key organisations advancing chronic care in Europe including providers, payers, suppliers, customers, policy-makers and health officials.

The European Leadership Summit on Chronic Care is the forum where government and industry leaders share successful initiatives and best practices. So far, the agenda includes case studies from 12 different countries.

Through the support of our partner organizations, we are creating a truly international event, reaching key health leaders in over 40 countries. An international delegation will enjoy this two-day networking opportunity, featuring visionary keynote addresses, controversial debates, implementation case studies, tutorials and informal roundtable discussions.

Four focused summits will give attendees a unique opportunity to discuss pertinent issues in depth and determine actionable plans with their colleagues:

  • IT Infrastructures, Electronic Health Records and Chronic Care
  • Aligning Financial Incentives and Restructuring Care
  • Telehealth and Remote Monitoring
  • Empowering Patients and Supporting Self-Care

Two best practice seminars will also explore disease specific initiatives for:

  • Diabetes
  • Cardiovascular and Lung Diseases

For further information and registration, please visit:
http://www.worldcongress.com/events/HL07080/

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...